Continued capital market volatility, coupled with a costly, tightening, and oftentimes burdensome debt landscape, has driven royalty monetization transactions into the mainstream as life sciences ...
DUBLIN--(BUSINESS WIRE)--The "Royalty Rates in Pharmaceutical and Biotechnology Deals" report has been added to ResearchAndMarkets.com's offering. Royalty Rates in Pharmaceutical and Biotechnology ...
“The fluctuation of average annual rates, as well as the generally downward trend of the rates in Chart 3, may have reflected the structural changes in the licensing market since the enactment of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results